OUTBACK: Phase III Trial of CRT ± Adjuvant CT in Women With Locally Advanced Cervical Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
In women with locally advanced cervical cancer, use of adjuvant carboplatin/paclitaxel after standard cisplatin-based CRT did not improve OS or PFS at 5 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 478 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.

Related Content

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Released: May 13, 2022

Commentary on immunotherapy in endometrial cancer with a focus on older patients, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: April 29, 2022

Clinical commentary with Eloise Chapman-Davis, MD, FACOG, on healthcare equity in gynecologic cancers, from Clinical Care Options (CCO)

Eloise Chapman-Davis, MD, FACOG Released: March 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings